Pre-settlement funding for mass tort and class action plaintiffs.
Multi-plaintiff litigation involving pharmaceutical injuries, defective devices, environmental contamination, and consumer products. Funding available for qualifying individual plaintiffs within mass tort proceedings.
Mass tort litigation involves a large number of plaintiffs with similar claims against a common defendant — typically a pharmaceutical manufacturer, medical device company, or industrial polluter. Individual plaintiffs within a mass tort often face years of litigation, limited visibility into case timeline, and ongoing financial pressure. Pre-settlement funding for mass tort plaintiffs provides individual, non-recourse advances based on each plaintiff's specific claim, independent of the overall mass tort resolution timeline.
Not every claim is a fit for funding. The factors below are the ones our underwriting team weighs most heavily when evaluating this case type. Meeting them does not guarantee approval, but it indicates a claim well-suited for a pre-settlement advance.
Mass tort advances are underwritten on a plaintiff-by-plaintiff basis, independent of the overall settlement timeline. We assess the procedural posture of the MDL, the strength of the underlying science, and the documentation supporting your individual claim, then estimate your expected individual recovery against the settlement and grid history of comparable mass torts. Because resolution can be years away, the timeline is priced explicitly into the advance.
Mass tort matters frequently take three to seven years from filing to individual distribution, depending on bellwether outcomes and global settlement timing.